Eli Lilly: third indication for Taltz in the US
(CercleFinance.com) - The FDA has approved Eli Lilly's Taltz in the treatment of ankylosing spondylitis, the pharmaceutical group said on Monday.
This is the third indication for Taltz, which is already authorized in the US for the treatment of psoriasis and psoriatic arthritis.
Ankylosing spondylitis - a chronic inflammatory rheumatism that reaches the spine and peripheral joints - affects over 1.6 million people in the United States.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
This is the third indication for Taltz, which is already authorized in the US for the treatment of psoriasis and psoriatic arthritis.
Ankylosing spondylitis - a chronic inflammatory rheumatism that reaches the spine and peripheral joints - affects over 1.6 million people in the United States.
Copyright (c) 2019 CercleFinance.com. All rights reserved.